First-year treatment patterns among new initiators of topical prostaglandin analogs

References

• Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90:262-7
   PubMed Web of Science ®Google Scholar
• Friedman DS, Wolfs RC, O'Colmain BJ, et al. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol 2004;122:532-8
   PubMed Web of Science ®Google Scholar
• American Academy of Ophthalmology. Preferred Practice Pattern. Primary Open-Angle Glaucoma. Limited Revision. San Francisco, CA: American Academy of Ophthalmology, 2003
   Google Scholar
• Klein BE, Klein R, Sponsel WE, et al. Prevalence of glaucoma. The Beaver Dam Eye Study. Ophthalmology 1992;99:1499-504
   PubMed Web of Science ®Google Scholar
• Schmier JK, Halpern MT, Jones ML. The economic implications of glaucoma: a literature review. Pharmacoeconomics 2007;25:287-308
   PubMed Web of Science ®Google Scholar
• Covert D, Robin AL. Adjunctive glaucoma therapy use associated with travoprost, bimatoprost, and latanoprost. Curr Med Res Opin 2006;22:971-6
   PubMed Web of Science ®Google Scholar
• Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology 2005;112:863-8
   PubMed Web of Science ®Google Scholar
• Schmier JK, Covert DW, Robin AL. Estimated first-year costs of prostaglandin analogs with/without adjunctive therapy for glaucoma management: a United States perspective. Curr Med Res Opin 2007;23:2867-75
   PubMed Web of Science ®Google Scholar
• Lewis RA, Katz GJ, Weiss MJ, et al. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J Glaucoma 2007;16:98-103
   PubMed Web of Science ®Google Scholar
• Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma 2008;17:350-5
   PubMed Web of Science ®Google Scholar
• Goldberg LD, Walt J. Cost considerations in the medical management of glaucoma in the US: estimated yearly costs and cost effectiveness of bimatoprost compared with other medications. Pharmacoeconomics 2006;24:251-64
   PubMed Web of Science ®Google Scholar
• Fremont AM, Lee PP, Mangione CM, et al. Patterns of care for open-angle glaucoma in managed care. Arch Ophthalmol 2003;121:777-83
   PubMed Web of Science ®Google Scholar
• Thomson Healthcare. Red Book Drug Topics. Montvale, NJ: Thomson Healthcare, 2008
   Google Scholar
• Practice Management Information Corporation. Medical Fees in the United States. Los Angeles, CA: Practice Management Information Corporation, 2008
   Google Scholar
• Fiscella RG, Green A, Patuszynski DH, et al. Medical therapy cost considerations for glaucoma. Am J Ophthalmol 2003;136:18-25
   PubMed Web of Science ®Google Scholar
• Platt R, Reardon G, Mozaffari E. Observed time between prescription refills for newer ocular hypotensive agents: the effect of bottle size. Am J Ophthalmol 2004;137:17-23
   Web of Science ®Google Scholar
• Fiscella R, Wilensky JT, Chiang TH, et al. Efficiency of instillation methods for prostaglandin medications. J Ocul Pharmacol Ther 2006;22:477-82
   PubMed Web of Science ®Google Scholar
• Quigley HA, Friedman DS, Hahn SR. Evaluation of practice patterns for the care of open-angle glaucoma compared with claims data: the Glaucoma Adherence and Persistency Study. Ophthalmology 2007;114:1599-606
   PubMed Web of Science ®Google Scholar
• Spooner JJ, Bullano MF, Ikeda LI, et al. Rates of discontinuation and change of glaucoma therapy in a managed care setting. Am J Manag Care 2002;8:S262-70
   PubMed Web of Science ®Google Scholar
• Ashaye AO, Adeoye AO. Characteristics of patients who dropout from a glaucoma clinic. J Glaucoma 2008;17:227-32
   PubMed Web of Science ®Google Scholar
• Juzych MS, Randhawa S, Shukairy A, et al. Functional health literacy in patients with glaucoma in urban settings. Arch Ophthalmol 2008;126:718-24
   PubMed Web of Science ®Google Scholar
• Brown MM, Brown GC, Spaeth GL. Improper topical self-administration of ocular medication among patients with glaucoma. Can J Ophthalmol 1984;19:2-5
   PubMed Web of Science ®Google Scholar
• Ashburn FSJr, Goldberg I, Kass MA. Compliance with ocular therapy. Surv Ophthalmol 1980;24:237-48
   PubMed Web of Science ®Google Scholar
• Kholdebarin R, Campbell RJ, Jin YP, et al. Multicenter study of compliance and drop administration in glaucoma. Can J Ophthalmol 2008;43:454-61
   PubMed Web of Science ®Google Scholar
• Norell SE, Granstrom PA. Self-medication with pilocarpine among outpatients in a glaucoma clinic. Br J Ophthalmol 1980;64:137-41
   PubMed Web of Science ®Google Scholar
• Schwartz GF, Platt R, Reardon G, et al. Accounting for restart rates in evaluating persistence with ocular hypotensives. Ophthalmology 2007;114:648-52
   PubMed Web of Science ®Google Scholar
• Friedman DS, Nordstrom B, Mozaffari E, et al. Glaucoma management among individuals enrolled in a single comprehensive insurance plan. Ophthalmology 2005;112:1500-4
   PubMed Web of Science ®Google Scholar
• Tsai T, Robin AL, Smith JP 3rd. An evaluation of how glaucoma patients use topical medications: a pilot study. Trans Am Ophthalmol Soc 2007;105:29-33; discussion
   PubMedGoogle Scholar
• Nordstrom BL, Friedman DS, Mozaffari E, et al. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol 2005;140:598-606
   PubMed Web of Science ®Google Scholar
• Varma R, Mohanty SA, Deneen J, et al. Burden and predictors of undetected eye disease in Mexican-Americans: the Los Angeles Latino Eye Study. Med Care 2008;46:497-506
   PubMed Web of Science ®Google Scholar
• Ramulu PY, Corcoran KJ, Corcoran SL, et al. Utilization of various glaucoma surgeries and procedures in Medicare beneficiaries from 1995 to 2004. Ophthalmology 2007;114:2265-70
   PubMed Web of Science ®Google Scholar